Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Axcan To Ax Itax?: Phase III Data Put Functional Dyspepsia Program In Jeopardy

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm awaits further analysis of international study and second Phase III trial data due by June before pulling plug; diabetic gastropathy program to continue.

You may also be interested in...

Axcan Takes Third Stab At FDA Approval For Helizide

The firm said it could launch the H. pylori bacteria agent in the first half of 2007.

Mobile Health Apps Could Disrupt Medical Technology Market– Report

Ernst & Young annual report highlights the importance of emerging “patient-empowering” and “information-leveraging” technologies, and their power to drive health care efficiencies.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts